Walter Armin Brown
#157,873
Most Influential Person Now
Walter Armin Brown's AcademicInfluence.com Rankings
Walter Armin Brownpsychology Degrees
Psychology
#3527
World Rank
#3976
Historical Rank
Clinical Psychology
#335
World Rank
#340
Historical Rank
Download Badge
Psychology Biology
Walter Armin Brown's Degrees
- Doctorate Psychiatry Stanford University
Why Is Walter Armin Brown Influential?
(Suggest an Edit or Addition)Walter Armin Brown's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. (2000) (474)
- Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database (2002) (451)
- Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. (2003) (359)
- The Placebo Effect: An Interdisciplinary Exploration (1997) (269)
- The dexamethasone suppression test: An overview of its current status in psychiatry (1987) (247)
- A Systematic Review of Comparative Efficacy of Treatments and Controls for Depression (2012) (225)
- The 24-hour dexamethasone suppression test in a clinical setting: relationship to diagnosis, symptoms, and response to treatment. (1979) (222)
- The placebo effect. (1998) (217)
- Sex Differences in Antidepressant Response in Recent Antidepressant Clinical Trials (2005) (206)
- Response to dexamethasone and subtype of depression. (1980) (204)
- Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder. (2010) (176)
- Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. (2002) (172)
- The Weariness of the Self: Diagnosing the History of Depression in the Contemporary Age (2011) (141)
- Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. (1997) (139)
- Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. (2001) (138)
- Antidepressants versus placebo in major depression: an overview (2015) (137)
- Are placebo controls necessary to test new antidepressants and anxiolytics? (2002) (134)
- Fluoxetine in the treatment of late luteal phase dysphoric disorder. (1991) (126)
- Serum testosterone and aggressiveness in hockey players. (1978) (114)
- Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. (2001) (114)
- Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. (2005) (103)
- Clinical features of depressed patients who do and do not improve with placebo (1992) (97)
- Placebo as a Treatment for Depression (1994) (96)
- Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. (2004) (95)
- Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? (1995) (93)
- Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. (2013) (91)
- Serum testosterone and sexual activity and interest in men (1978) (90)
- Pituitary-adrenal disinhibition in depression: Marker of a subtype with characteristic clinical features and response to treatment? (1981) (86)
- Testosterone and components of aggressive and sexual behavior in man. (1977) (76)
- The persistence of the placebo response in antidepressant clinical trials. (2008) (69)
- Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987‐2013 (2017) (68)
- Why Has the Antidepressant–Placebo Difference in Antidepressant Clinical Trials Diminished over the Past Three Decades? (2010) (67)
- Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction (1993) (67)
- The dexamethasone suppression test and completed suicide (1990) (65)
- Psychological Function in Individuals with Amyotrophic Lateral Sclerosis (ALS) (1970) (64)
- Low serum prolactin and early relapse following neuroleptic withdrawal. (1981) (60)
- Endocrine correlates of sadness and elation. (1993) (58)
- Effect of apomorphine on growth hormone release in humans. (1973) (54)
- BMI, sex, and antidepressant response. (2007) (54)
- Is interpersonal psychotherapy superior to supportive psychotherapy? (1996) (53)
- DEXAMETHASONE SUPPRESSION TEST IDENTIFIES SUBTYPES OF DEPRESSION WHICH RESPOND TO DIFFERENT ANTIDEPRESSANTS (1980) (51)
- Massachusetts General Hospital Comprehensive Clinical Psychiatry (2009) (50)
- Tolerance to the prolactin-elevating effect of neuroleptics (1981) (48)
- Prolactin and neuroleptic drugs. (1988) (48)
- Side effects and the "blindability" of clinical drug trials. (1992) (47)
- Placedo response in depression: A search for predictors (1988) (46)
- Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease: A Double-blind, Placebo-Controlled Study (1995) (44)
- Response to neuroleptic drugs as a device for classifying schizophrenia. (1989) (43)
- Cortisol, growth hormone, free fatty acids, and experimentally evoked affective arousal. (1975) (42)
- Neural and endocrine correlates of sadness in women: implications for neural network regulation of HPA activity. (2004) (42)
- Serum testosterone concentration and penile tumescence changes in men (1980) (40)
- Serum prolactin and clinical state during neuroleptic treatment and withdrawal. (1979) (38)
- Psychological functioning of bipolar manic-depressives in remission. (1978) (38)
- Psychologic and neuroendocrine response to methylphenidate. (1977) (37)
- The dexamethasone suppression test and pituitary-adrenocortical function. (1985) (37)
- Fluoxetine in the treatment of premenstrual syndrome. (1990) (36)
- A simple laboratory method for inducing anger: a preliminary investigation. (1999) (35)
- Stress-induced growth hormone release: psychologic and physiologic correlates. (1976) (35)
- Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review (2021) (34)
- Low serum neuroleptic levels predict relapse in schizophrenic patients. (1982) (34)
- The Placebo Effect in Clinical Practice (2012) (32)
- Alleviation of manic symptoms with catecholamine agonists. (1979) (32)
- Differential effects of neuroleptic agents on the pituitary-gonadal axis in men. (1981) (31)
- Neuroendocrine and cognitive responses to amphetamine in adolescents with a history of attention deficit disorder. (1986) (31)
- Age and the dexamethasone suppression test: Results from a broad unselected patient population (1992) (29)
- Acute psychologic and neuroendocrine effects of dextroamphetamine and methylphenidate (1978) (27)
- Dissociation of growth hormone and cortisol release following apomorphine. (1974) (26)
- Methylphenidate increases serum growth hormone concentrations. (1976) (25)
- The clinical discovery of imipramine. (2015) (25)
- Decreased suicide rates in recent antidepressant clinical trials (2018) (25)
- Prolactin and neuroleptic drugs. (1988) (24)
- Expectation, the placebo effect and the response to treatment. (2015) (23)
- Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients. (1987) (23)
- Results of the dexamethasone suppression test in psychiatric patients with and without weight loss. (1985) (23)
- Mathematical models of complex dose-response relationships: implications for experimental design in psychopharmacologic research. (1992) (22)
- Predictors of placebo response in depression. (1988) (20)
- Prolactin shifts after neuroleptic withdrawal (1990) (20)
- Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. (2007) (20)
- Psychiatric Diagnosis and Clinical Trial Completion Rates: Analysis of the FDA SBA Reports (2007) (20)
- Are the colors and shapes of current psychotropics designed to maximize the placebo response? (2010) (20)
- The conundrum of depression clinical trials: one size does not fit all (2018) (20)
- DIMENSIONS OF CONTROL: CORRELATIONS BETWEEN MMPI AND I-E SCORES ' (1971) (20)
- Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate. (1985) (20)
- Pre-treatment pituitary-adrenocortical status and placebo response in depression. (1987) (19)
- The Relationship of Antenatal and Perinatal Psychologic Variables to Use of Drugs in Labor (1972) (18)
- Does the increasing placebo response impact outcomes of adult and pediatric ADHD clinical trials? Data from the US Food and Drug Administration 2000-2009. (2017) (18)
- The placebo enigma in antidepressant clinical trials. (2001) (18)
- Serum prolactin and tardive dyskinesia. (1981) (17)
- Use of alternative medicine. (2001) (17)
- Psychological Care During Pregnancy and the Postpartum Period (1979) (17)
- Who should receive antidepressants: suggestions from placebo treatment. (1991) (16)
- Dexamethasone suppresses beta-endorphin in humans (1985) (16)
- Antidepressant–placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity (2011) (15)
- Is light treatment a placebo? (1990) (15)
- Diagnostic heterogeneity and the DST in consecutive psychiatric admissions (1985) (15)
- Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews. (2014) (14)
- Comparison of testing saliva and serum for detection of antibody to human immunodeficiency virus in Jamaica, West Indies. (2000) (14)
- Neuroleptic bioavailability, psychosocial factors, and clinical status: A 1-year study of schizophrenic outpatients after dose reduction (1986) (14)
- The dexamethasone suppression test: clinical applications. (1981) (14)
- Which Depressed Patients Should Receive Antidepressants? (1994) (14)
- Cortisol level response to 1- and 2-mg doses of dexamethasone. (1983) (14)
- Seven women: a prospective study of postpartum psychiatric disorders. (1972) (13)
- Harnessing the placebo effect. (1998) (13)
- Magnitude and Pattern of Placebo Response in Clinical Trials of Oral Antihyperglycemic Agents: Data From the U.S. Food and Drug Administration, 1999–2015 (2018) (13)
- Are patients with depression at heightened risk of suicide as they begin to recover (2009) (13)
- The Psychotherapy of Hope: The Legacy of Persuasion and Healing (2012) (13)
- Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome. (1993) (13)
- The Effect of Anticonvulsants on the Dexamethasone Suppression Test (1989) (13)
- All in the mind? (2003) (13)
- Neuroleptic dose reduction in persistently psychotic patients. (1989) (12)
- Pituitary-adrenal regulation over multiple depressive episodes (1982) (11)
- Understanding and Using the Placebo Effect (2006) (11)
- Are patients with depression at heightened risk of suicide as they begin to recover? (2009) (11)
- Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients (2004) (11)
- Handbook of Contemporary Neuropharmacology (2007) (10)
- Testosterone and Human Behavior (1980) (10)
- Effect of age on DST results. (1982) (10)
- Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor. (1986) (9)
- Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016 (2018) (9)
- Anger arousal by a motion picture: a methodological note. (1977) (9)
- Neuroleptic dose reduction for schizophrenic outpatients: a three-year follow-up study. (1988) (9)
- Acetylcholine and affective disorder (2005) (9)
- Single-dose fluoxetine in management of premenstrual syndrome. (1992) (8)
- Depression in Parkinson Disease (2006) (8)
- Prenatal psychological state and the use of drugs in labor. (1972) (8)
- Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interviews (SIGMA-RAPS) compared to trials using traditional semi-structured interviews (2014) (8)
- Low serum neuroleptic levels predict relapse in schizophrenic patients (1983) (7)
- Prolactin levels and effects of neuroleptics. (1983) (7)
- The placebo effect in psychiatric practice. (2017) (7)
- Inappropriate amputation requests. (1981) (7)
- Pharmacologic Treatments for Premenstrual Dysphoric Disorder (1996) (6)
- Effects of thioridazine on serum testosterone. (1978) (6)
- Are antidepressants as ineffective as they look (2002) (6)
- Radioreceptor assay and high-performance liquid chromatography yield similar results for serum thioridazine and its major metabolites. (1988) (5)
- The volunteer rescue squad: the impact of a group on the psychological adaptation of its members. (1973) (5)
- Neuroleptic nonresponse and affective symptoms: A 2-year prospective study of schizophrenic outpatients (1989) (5)
- The dexamethasone suppression test in the identification subtypes of depression differentially responsive to antidepressants [proceedings]. (1981) (5)
- Magnitude and pattern of placebo response in clinical trials of antiepileptic medications: Data from the Food and Drug Administration 1996-2016. (2018) (5)
- How expectation works: psychologic and physiologic pathways. (2015) (5)
- Dr. White and Colleagues Reply (1993) (4)
- Serum neuroleptic levels in the maintenance treatment of schizophrenia. (1983) (4)
- Behavioral instruction for a patient's relative to increase antihypertensive compliance. (1985) (4)
- Brain Stimulation Methods for Treating Depression (2006) (4)
- Acknowledging Preindustrial Patterns of Sleep May Revolutionize Approach to Sleep Dysfunction (2006) (4)
- Out of Its Mind--Psychiatry in Crisis: A Call for Reform (2001) (4)
- Dr. Brown and Associates Reply (1986) (4)
- Consistency of pituitary-adrenocortical function across multiple psychiatric hospitalizations (1986) (4)
- New-Onset Psychosis and Emergence of Suicidal Ideation With Aripiprazole (2010) (3)
- Mortality during US FDA clinical trials in patients with diabetes, hypertension, depression and schizophrenia (2018) (3)
- Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse. (1995) (3)
- Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings. (1983) (3)
- The Impact of Underpowered Studies on Clinical Trial Results. (2018) (3)
- FLUOXETINE AND PREOCCUPATION WITH SUICIDE. REPLY (1991) (3)
- Suicide risk analysis among patients assigned to psychotropics and placebo. (2006) (3)
- Serum levels of fluphenazine in schizophrenic outpatients maintained on two reduced doses of fluphenazine decanoate (1994) (3)
- Seven Women: A Prospective Study of Postpartum Psychiatric Disorders †. (1973) (3)
- Screening depressives for causative medical illness; the example of thyroid function testing: II. Hypothesis testing in ambulatory depressives (1993) (3)
- The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection (1992) (3)
- Cognitive and affective probes of the HPA axis: a SPECT study. (2004) (3)
- The meaning of success in a person with a "success phobia". (1971) (3)
- The Cult of Pharmacology: How America Became the World’s Most Troubled Drug Culture (2007) (3)
- Before Prozac: The Troubled History of Mood Disorders in Psychiatry (2009) (3)
- PMS: A Quiet Breakthrough (1996) (3)
- Neuroleptics and Prolactin (1984) (2)
- Consultation-liaison psychiatry: current responsibilities. (1976) (2)
- Neuroendocrine correlates of clinical response during withdrawal from chlordiazepoxide. (1978) (2)
- Response to letter from Lipsitz et al. (2014) (2)
- Good News about Depression (2007) (2)
- Ketamine and NMDA Receptor Antagonists for Depression (2007) (2)
- Addressing Psychotherapy Challenges in the Medication Visit: A Pilot Course on Brief Psychotherapeutic Interventions (2014) (2)
- Research on Psychedelics Making a Comeback (2007) (2)
- Is "medication visit" a misnomer? Psychotherapy challenges in 90862. (2011) (2)
- Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics. (1989) (2)
- Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy. (1997) (2)
- Sex Differences in Growth Hormone Response (1974) (1)
- Effect of apomorphine on serum prolactin level in the male. (1975) (1)
- The Treatment Situation (2012) (1)
- Fluoxetine and preoccupation with suicide. (1991) (1)
- Ancient Sleep in Modern Times (2006) (1)
- Consistently Modest Antidepressant Effects in Clinical Trials: the Role of Regulatory Requirements. (2021) (1)
- Efficacy and safety of anti-manic agents in children and adults. (2012) (1)
- Reply to Kocsis Letter (2010) (1)
- How a Psychopharmacology Clinical Trial Site in the Seattle Area Managed Clinical Trials and Patient Care During the COVID-19 Pandemic (2020) (1)
- Pseudodementia: Issues in Diagnosis (2005) (1)
- 183 The role of immune measures in psychosis and stress sensitivity in schizophrenia (1997) (0)
- A CORRECTION. (1912) (0)
- RAPID COMMUNICATION Serum Testosterone and Aggressiveness in Hockey Players (2005) (0)
- Studies of response to dexamethasone in psychiatric patients [proceedings]. (1980) (0)
- Post dose reduction survival in the maintenance treatment of schizophrenia (1990) (0)
- Prenatal psychological stale and the use of drugs in labor (1973) (0)
- The House of Hope and Fear: Life in a Big City Hospital (2010) (0)
- Broken Sleep May Be Natural Sleep (2007) (0)
- Mortality Risk With Mirtazapine and Estimating Suicide Risk. (2015) (0)
- Emergency Psychiatry: Principles and Practice (2009) (0)
- Comment on the Advisability of Therapists Conducting Physical Exams (1968) (0)
- Pretreatment pituitary-adrenocortical status in depression and response to antidepressant, placebo and psychosocial treatment (1989) (0)
- Dopamine Agonists, Pathologic Gambling, and Parkinson Disease (2006) (0)
- Decreased suicide rates in recent antidepressant clinical trials (2018) (0)
- PANDAS: Nonexistent or Simply Rare? (2005) (0)
- History of Psychiatry and Medical Psychology (2008) (0)
- SERUM PROLACTIN AS AN INDICATOR OF ALTERATIONS IN BRAIN DOPAMINE SYSTEMS (1979) (0)
- Psychotherapy and Placebo (2012) (0)
- Using the Placebo Response (2012) (0)
- Commentary on “Menstrually Related Disorders: Points of Consensus, Debate, and Disagreement” (1993) (0)
- Research report BMI, sex, and antidepressant response ☆ (2007) (0)
- Reply to Millman and Opler. (2015) (0)
- Letter: Sex differences in growth hormone response. (1974) (0)
- Ameliorating Stressors May Alleviate MS (2007) (0)
- Pretreatment Pituitary-Adrenocortical Status: Prediction of Placebo Response in Depression (1989) (0)
- Dopamine Agonists, Pathologic Gambling, and Parkinson Disease: A Connection? (2006) (0)
- The Ethics of Placebo Use in Research (2012) (0)
- Mental Health Professionals' Attitudes Toward the Family's Role in Care ofthe Mentally Ill (1989) (0)
- Conflict of Interest: Financial Gain is Just One of Many Motives (2002) (0)
- Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interviews (SIGMA-RAPS) compared to trials using traditional semi-structured interviews (2014) (0)
- Love of Garbage (2007) (0)
- Ssris and Deliberate Self-harm Ssris and Deliberate Self-harm (0)
- The Human Effect in Medicine: Theory, Research and Practice (2001) (0)
- Effectiveness Is Not Enough: ECT and Psychostimulants (1996) (0)
- Psychotropic drugs do not interfere with radioligand assays for prolactin, cortisol, and growth hormone. (1979) (0)
- Handbook of clinical psychoneuroendocrinology Edited by Nemeroff, C.B. and Loosen, P.T., Guilford Press, New York, 1987. 502 pages, U.S. $66 (1988) (0)
- Finessing the Fine Line Between Pain Management and Opioid Addiction (2007) (0)
- How Does Placebo Differ from No Treatment (2012) (0)
- Point of view: changing fashions in psychiatry. (2004) (0)
- Reply to Commentaries (2010) (0)
- The Brain, Biochemistry, and Behavior (1984) (0)
- Book Review: The Madness of Fear (2018) (0)
- IS INTERPERSONAL PSYCHOTHERAPY SUPERIOR TO SUPPORTIVE PSYCHOTHERAPY ? AUTHORS' REPLY (1996) (0)
- The Perils of Compulsive Hoarding and How to Intervene (2006) (0)
- Conditioning and the Placebo Response (2012) (0)
- Colds , asthma , high blood pressure and heart disease are among the many conditions that can respond to treatment with a placebo . Should doctors be prescribing sugar pills ? (0)
- Teeth. By Simon Hillson (1988) (0)
- Our visitor from Vienna. (2010) (0)
- Treating Dementia: Do We Have a Pill for It? (2010) (0)
- Neuroendocrine Regulation and Altered Behaviour (1983) (0)
- Insights Into Mood and Cognitive Disability in MS: Recognition and Treatment (2007) (0)
- Variations in Placebo Response (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Walter Armin Brown?
Walter Armin Brown is affiliated with the following schools:
